본문으로 건너뛰기
← 뒤로

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia.

증례보고 2/5 보강
Journal of cutaneous pathology 📖 저널 OA 38.1% 2021: 0/2 OA 2025: 0/3 OA 2026: 16/34 OA 2021~2026 2026 OA Myeloproliferative Neoplasms: Diagno
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-30
OpenAlex 토픽 · Myeloproliferative Neoplasms: Diagnosis and Treatment Chronic Myeloid Leukemia Treatments Acute Myeloid Leukemia Research

Christie-Nguyen B, El Achi H, Iashvili L, Wahed A, Mai B, Armstrong J

📝 환자 설명용 한 줄

Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Bennett Christie‐Nguyen, Hanadi El Achi, et al. (2026). A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia.. Journal of cutaneous pathology. https://doi.org/10.1111/cup.70114
MLA Bennett Christie‐Nguyen, et al.. "A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia.." Journal of cutaneous pathology, 2026.
PMID 41963109 ↗
DOI 10.1111/cup.70114

Abstract

Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML). Here, we present a 34-year-old Hispanic male with multiple bilateral lower extremity lesions, right buttock and leg pain, fatigue, and splenomegaly, who was found to have chronic-phase CML. Punch biopsy of one of the skin lesions demonstrated dermal infiltration by maturing hematopoietic elements, including granulocytes, megakaryocytes, and erythroid precursors, with fluorescence in situ hybridization (FISH) testing confirming a neoplastic extramedullary hematopoietic infiltrate with the presence of BCR::ABL1 fusion. Initial treatment included hydroxyurea and dasatinib; however, after chronic-phase CML was confirmed, therapy was transitioned to imatinib, resulting in resolution of B symptoms, normalization of WBC counts, and reduced leg swelling. This case underscores the importance of distinguishing CEH from aggressive disease states, such as blast-phase CML or myeloid sarcoma, through comprehensive histopathological and immunohistochemical analysis.
🔓 OA PDF 열기